Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS

Abstract

There are differences in HCV prevalence and rate of seroconversion at the country and the hemodialysis facility level. The observed variation suggests opportunities for improved HCV outcomes.

Risk of Kaposi's sarcoma and of other cancers in Italian renal transplant patients

“…Renal transplant and Kaposi's sarcoma D Serraino et al among dialysis patients are high (Petrosillo et al, 1993;Fissell et al, 2004). The higher SIR for liver cancer found in our study than elsewhere may also be related to the fact that infection with hepatitis C virus in the recipient is not generally considered a contraindication for renal transplant in Italy.…”

The Impact of Transplantation with Deceased Donor Hepatitis C-Positive Kidneys on Survival in Wait-Listed Long-term Dialysis Patients

“…According to the recent DOPPS (a prospective observational) study, the prevalence of HCV among American dialysis patients at the start of dialysis was 7.3%, while the prevalence of HCV among those who had been on dialysis for 10 years of more was 22.5%, and was 39% for those who had been on dialysis for 15 years or more (9). Comparable trends have also been reported from European regional studies (10).…”

Mortality among hemodialysis patients in Europe, Japan, and the United States: Case-mix effects

“…4 Hepatitis C cases were defined as those who were hepatitis C virus (HCV) antibody positive or who had a history of HCV diagnosis. 5 The case definitions for the other comorbid diseases are delineated in the appendix to the original comorbidities report. 3 Hepatitis B seroconversion was defined as documented change from negative HBV surface antigen status at entry to positive while on study.…”